XCancer

A Phase I, Open-Label, Escalation and Expansion Study to Evaluate Dosimetry, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CEA-Pre-Targeted 212Pb Therapy in Participants With Metastatic Colorectal Cancer

Description:

This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.

Sponsor:

Hoffmann-La Roche

Phase:

Phase 1

Contacts:

Reference Study ID Number: BP45930

global-roche-genentech-trials@gene.com

888-662-6728

Government Study Link:

NCT07416552 - Click here to see study on

ClinicalTrials.gov

212Pb-DOTAM

Isotope(s):
Target(s):
  • SSTR2

203Pb-DOTAM

Isotope(s):
Target(s):
  • SSTR2